116986-13-1

Basic information

• Product Name: 3-BROMOMETHYL-PYRIDINE-2-CARBONITRILE
• Synonyms: 3-BROMOMETHYL-PYRIDINE-2-CARBONITRILE;3-BroMoMethyl-2-cyanopyridine, 97%;3-(broMoMethyl)picolinonitrile;3-(bromomethyl)-2-Pyridinecarbonitrile
• CAS NO: 116986-13-1
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.032
• Product Categories: Pyridine series;Methyl Halides;Pyridines;Methyl Halides
• Mol File: 116986-13-1.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 308.2 °C at 760 mmHg
• Flash Point: 140.2 °C
• Appearance: /
• Density: 1.6 g/cm³
• Vapor Pressure: 0.00069mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.23±0.10(Predicted)
• CAS DataBase Reference: 3-BROMOMETHYL-PYRIDINE-2-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMOMETHYL-PYRIDINE-2-CARBONITRILE(116986-13-1)
• EPA Substance Registry System: 3-BROMOMETHYL-PYRIDINE-2-CARBONITRILE(116986-13-1)

Safety Data

• RIDADR: UN3439
• Hazardous Substances Data: 116986-13-1(Hazardous Substances Data)

Usage

General Description

3-Bromomethyl-pyridine-2-carbonitrile is a chemical compound with the molecular formula C7H5BrN2. It is a white to off-white solid that is used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is commonly used as a building block in the production of various drug candidates and APIs, and it is also used in the agrochemical industry for the synthesis of fungicides, herbicides, and insecticides. The compound is known to be a highly reactive and versatile chemical, making it a valuable tool for organic synthesis and drug discovery research. However, it should be handled with caution as it is a potentially hazardous substance and may cause skin and eye irritation upon contact.

InChI:InChI=1/C7H5BrN2/c8-4-6-2-1-3-10-7(6)5-9/h1-3H,4H2

Upstream product

• 20970-75-6 2-cyano-3-methylpyridine 

Downstream Products

• 81109-81-1 2-cyano-3-(phenylthiomethyl)pyridine 
• 131747-56-3 3-(hydroxymethyl)pyridine-2-carbonitrile 
• 55942-66-0 3-(phenoxymethyl)pyridine-2-carboxylic acid 
• 55942-67-1 3-(phenylthiomethyl)pyridine-2-carboxylic acid 
• 126570-66-9 3-[(3-chlorophenyl)thiomethyl]-2-cyanopyridine 
• 5912-34-5 2-cyano-pyridin-3-yl-acetonitrile 
• 1324006-68-9 7-aza-5,6-dihydro-2,3-dimethoxy-5-oxo-11H-indeno[1,2-c]isoquinoline 
• 5912-35-6 8-bromo-[1,7]naphthyridin-6-ylamine 
• 5912-36-7 1,7-naphthyridin-6-amine 
• 1201843-32-4 N-(2-chloro-5-(1,7-naphthyridin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 916800-04-9 3-((2,6-dichlorophenoxy)methyl)-2-picolinenitrile 

Relevant articles and documents

Synthesis and properties of a novel Cu(II)-pyridineoxazoline containing polymeric catalyst for asymmetric Diels-Alder reaction

A novel pyridineoxazoline (PyOx) containing optically active polymer, poly[(-)-(S)-4-tert-butyl-2-(3-vinylpyridin-2-yl)-oxazoline], was prepared via the radical polymerization of (-)-(S)-4-tert-butyl-2-(3-vinylpyridin-2-yl)-oxazoline. Its complex with Cu(OTf)2 was employed to catalyse the homogeneous Diels-Alder (D-A) reaction of 2-alkenoyl pyridine N-oxide and cyclopentadiene in tetrahydrofuran. The polymeric catalyst showed a 5 fold faster reaction rate and a 2.5 fold higher enantio-selectivity than the Cu(II) complex of (-)-(S)-4-tert-butyl-2-(3-methylpyridin-2-yl)-oxazoline, a low molecular mass model compound. This was rationalized by the constrained environment around catalytic site provided by the polymer backbone in terms of CD spectrometry results. The polymer complex was easily recycled by the precipitation method, and only a slight decrease of reactivity and enantio-selectivity was observed after 5 cycles.

ETHER LINKED TRIAZOLES AS NRF2 REGULATORS

The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof:

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.